{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:56:15Z","timestamp":1784976975501,"version":"3.55.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"7_Supplement_3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.2146\/ajhp100076","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T21:02:32Z","timestamp":1269378152000},"page":"S9-S19","source":"Crossref","is-referenced-by-count":9,"title":["Managing osteoporosis in postmenopausal women"],"prefix":"10.1093","volume":"67","author":[{"given":"Sheryl F.","family":"Vondracek","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Denver School of Pharmacy, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104103012000_b1-06700s9","unstructured":"National Osteoporosis Foundation. Clinician\u2019s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. www.nof.org\/professionals\/Clinicians_Guide.htm (accessed 2009 Dec 2)."},{"key":"key\n\t\t\t\t2019041104103012000_b2-06700s9","first-page":"1483","article-title":"Osteoporosis and other metabolic bone diseases","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"O\u2019Connell","year":"2008","edition":"7th ed."},{"key":"key\n\t\t\t\t2019041104103012000_b3-06700s9","unstructured":"U.S. Department of Health and Human Services. 2008 Physical activity guidelines for Americans. www.health.gov\/paguidelines\/ (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b4-06700s9","unstructured":"U.S. Department of Agriculture. Dietary guidelines for Americans 2005. www.health.gov\/dietaryguidelines\/dga2005\/document\/pdf\/DGA2005.pdf (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b5-06700s9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00198-006-0109-y","article-title":"Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women","volume":"17","author":"Hallstr\u00f6m","year":"2006","journal-title":"Osteoporosis Int."},{"key":"key\n\t\t\t\t2019041104103012000_b6-06700s9","unstructured":"National Institutes of Health, Office of Dietary Supplements. Dietary supplement fact sheet: calcium. http:\/\/ods.od.nih.gov\/factsheets\/calcium.asp (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b7-06700s9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int."},{"key":"key\n\t\t\t\t2019041104103012000_b8-06700s9","unstructured":"Centers for Disease Control and Prevention. Falls\u2014older adult. What YOU can do to prevent falls (brochure). www.cdc.gov\/HomeandRecreationalSafety\/pubs\/English\/brochure_Eng_desktop-a.pdf (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b9-06700s9","unstructured":"Centers for Disease Control and Prevention. Check for safety: a home fall prevention checklist for older adults. www.cdc.gov\/ncipc\/pub-res\/toolkit\/Falls_ToolKit\/DesktopPDF\/English\/booklet_Eng_desktop.pdf (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b10-06700s9","unstructured":"National Osteoporosis Foundation. What you should know about calcium. www.nof.org\/prevention\/calcium2.htm (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b11-06700s9","unstructured":"U.S. Food and Drug Administration. How to understand and use the nutrition facts label. www.cfsan.fda.gov\/~dms\/foodlab.html (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b12-06700s9","unstructured":"U.S. Pharmacopeia. The USP dietary supplement verification program. www.usp.org\/USPVerified\/dietarySupplements\/ (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b13-06700s9","unstructured":"National Osteoporosis Foundation. Prevention: vitamin D. www.nof.org\/prevention\/vitaminD.htm (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b14-06700s9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jn\/136.4.1123","article-title":"Barriers to optimizing vitamin D3 intake for the elderly","volume":"136","author":"Heaney","year":"2006","journal-title":"J Nutr."},{"key":"key\n\t\t\t\t2019041104103012000_b15-06700s9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b16-06700s9","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"key\n\t\t\t\t2019041104103012000_b17-06700s9","unstructured":"Bone health and osteoporosis: a report of the Surgeon General. Chapter 2: the basics of bone in health and disease. www.surgeongeneral.gov\/library\/bonehealth\/chapter_2.html (accessed 2009 Dec 7)."},{"key":"key\n\t\t\t\t2019041104103012000_b18-06700s9","volume-title":"Fosamax package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b19-06700s9","volume-title":"Fosamax Plus D package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b20-06700s9","volume-title":"Boniva tablets package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104103012000_b21-06700s9","volume-title":"Boniva injection package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b22-06700s9","volume-title":"Actonel package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b23-06700s9","volume-title":"Reclast package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b24-06700s9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/jc.2008-2241","article-title":"The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women","volume":"94","author":"Grey","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"key\n\t\t\t\t2019041104103012000_b25-06700s9","volume-title":"Evista package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104103012000_b26-06700s9","volume-title":"Miacalcin nasal spray package insert","year":"2006"},{"key":"key\n\t\t\t\t2019041104103012000_b27-06700s9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b28-06700s9","volume-title":"Forteo package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b29-06700s9","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"key\n\t\t\t\t2019041104103012000_b30-06700s9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"key\n\t\t\t\t2019041104103012000_b31-06700s9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/9780470623992.ch19","article-title":"Menopause","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Reid","year":"2008","edition":"7th ed"},{"key":"key\n\t\t\t\t2019041104103012000_b32-06700s9","first-page":"3178","article-title":"Raloxifene hydrochloride","volume-title":"AHFS drug information 2009","author":"McEvoy","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b33-06700s9","first-page":"3286","article-title":"Calcitonin","volume-title":"AHFS drug information 2009","author":"McEvoy","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b34-06700s9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep."},{"key":"key\n\t\t\t\t2019041104103012000_b35-06700s9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone."},{"key":"key\n\t\t\t\t2019041104103012000_b36-06700s9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041104103012000_b37-06700s9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041104103012000_b38-06700s9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"key\n\t\t\t\t2019041104103012000_b39-06700s9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b40-06700s9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041104103012000_b41-06700s9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b42-06700s9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b43-06700s9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b44-06700s9","unstructured":"Confavreux C Canoui-Poitrine F Tainturier V . Persistence at 1 year of several oral antiosteoporotic drugs as a function of dosing frequency: a prospective study. J Bone Miner Res. 2009; 24(Suppl 1): abstract A09002577. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=f6001643-3a8e-4efd-84bd-88ea9cd56ec1 (accessed 2009 Dec 8)."},{"key":"key\n\t\t\t\t2019041104103012000_b45-06700s9","unstructured":"International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don\u2019t continue with treatment. www.iofbonehealth.org\/publications\/the-adherence-gap.html (accessed 2009 Nov 24)."},{"issue":"(Suppl 2)","key":"key\n\t\t\t\t2019041104103012000_b46-06700s9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","article-title":"Impact of osteoporosis treatment adherence on fracture rates in North America and Europe","volume":"122","author":"Siris","year":"2009","journal-title":"Am J Med."},{"key":"key\n\t\t\t\t2019041104103012000_b47-06700s9","unstructured":"Traveling with Forteo. www.forteo.com\/secure\/user\/traveling.jsp (accessed 2010 Jan 9)."},{"key":"key\n\t\t\t\t2019041104103012000_b48-06700s9","volume-title":"Zometa package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104103012000_b49-06700s9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","article-title":"Bisphosphonate associated osteonecrosis of the jaw","volume":"36","author":"Khan","year":"2009","journal-title":"J Rheumatol."},{"key":"key\n\t\t\t\t2019041104103012000_b50-06700s9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041104103012000_b51-06700s9","unstructured":"Amgen provides update on status of Prolia (denosumab) biologics application (BLA) submitted to the U.S. Food and Drug Administration. Oct19, 2009. www.psa-rising\/wiredbird\/amgen_denosumab-101909.htm (accessed 2010 Feb 4)."},{"key":"key\n\t\t\t\t2019041104103012000_b52-06700s9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2146\/ajhp070302","article-title":"ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults","volume":"65","author":"American Society of Health-System Pharmacists","year":"2008","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019041104103012000_b53-06700s9","unstructured":"FDA classified Prolia (denosumab) complete response submission and targets action date. February19, 2010. www.amgen.com\/media\/media_pr_detail.jsp?releaseod=1393314 (accessed 2010 Feb 23)."},{"key":"key\n\t\t\t\t2019041104103012000_b54-06700s9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract."},{"key":"key\n\t\t\t\t2019041104103012000_b55-06700s9","unstructured":"World Health Organization. FRAX WHO fracture risk assessment tool: US (black). http:\/\/www.shef.ac.uk\/FRAX\/tool.jsp?locationValue=1 (accessed 2009 Dec 2)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/7_Supplement_3\/S9\/28343690\/ajhp00s9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T10:29:23Z","timestamp":1558952963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/7_Supplement_3\/S9\/5129524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":55,"journal-issue":{"issue":"7_Supplement_3","published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100076","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,4,1]]},"published":{"date-parts":[[2010,4,1]]}}}